Bionpharma endeavors to bring quality generics to the market across therapeutic areas. For doing so we constantly evaluate products that can add value to all stake holders and the health‐Care system. This enables us to work on the development of these products and put them through the FDA approval process. Bionpharma is engaged In product development in different geographies across the World.
James Gale

Mr. Gale is the founding partner of Signet Healthcare Partners. He initiates investments and provides active management oversight to a number of the portfolio companies. He is currently the Chairman of the Board of Alpex Pharma S.A. and Pfenex Inc., and also serves on the Board of Directors of Arbor Pharmaceutical, Spepharm AG, Paladin Laboratories, IGI, Inc., and Anteis SA. Prior to founding Signet Healthcare Partners, Mr. Gale was head of principal investment activities and head of investment banking for Gruntal & Co., LLC. While at Gruntal, Mr. Gale’s investment activities included Andrx Corporation, Royce Laboratories (merged with Watson Pharmaceuticals), Lifecell Corporation, Neurocrine Biosciences, and BML Pharmaceuticals (acquired by Endo Pharmaceuticals).
Prior to joining Gruntal, he originated and managed private equity investments for the Home Insurance Co., Gruntal’s parent. Earlier in his career, Mr. Gale was a senior investment banker at E.F. Hutton & Co.
Mr. Gale received his Masters of Business Administration from the University of Chicago.
Read More..

David Goodman

Dr. David Goodman is Chief Executive Officer of Pharmascience, which is today the 2nd largest privately-owned pharmaceutical company in Canada. Dr. Goodman obtained his Bachelor degree in Commerce from McGill University, and his Ph.D. in pharmacology from the University of Virginia. Upon graduation, he began his career at Pharmascience in Business Development and has gained significant experience in progressively senior international and domestic roles. Under Dr. Goodman's leadership, Pharmascience has gone from being a strictly Canadian company to becoming an important player on the global stage. Pharmascience strives to be the first company to launch its generic pipeline in Canada, Europe and various markets throughout the world.
Dr. Goodman's success is his belief and insistence on major and constant investment in internal and external R&D programs, as well as in employee development.
Read More..

Venkat Krishnan

Read More..

Richard Van Dyune

Richard (Dick) Van Duyne joined Daiichi Sankyo in 2003 as Global Head of Business Development, chairing the Senior Licensing Committee and working directly with senior management in Tokyo, the U.S. and Europe on key licensing and business development projects. He held this position until April 1, 2013, when he moved to a senior advisor role, working with the CEO on special projects. He began his career in 1979 as an associate at the law firm of White & Case in New York and Stockholm.
In 1984 he joined the Legal Division of Warner-Lambert Company. He served in various capacities in the Legal Division until moving to Licensing in 1992. In 1996 he was named Vice President Licensing & Business Development, serving in that role until Warner- Lambert was acquired by Pfizer in 2000.
After a brief time as co-founder of MedPointe, a specialty pharmaceutical company, Mr. Van Duyne joined Pharmacia Corporation as Senior Vice President of Corporate Development, serving in that capacity until Pharmacia was acquired by Pfizer in 2003. Mr. Van Duyne received his B.S. in Economics from the University of Pennsylvania, his M.B.A. from the Wharton Graduate Division, University of Pennsylvania and his J.D. from Stanford University.
Read More..


Carole Ben-Maimon, M.D. previously served as president of Global Pharmaceuticals, Impax Laboratories’ generic pharmaceutical division. In this role, Dr. Ben-Maimon reported to Impax's president and chief executive officer and was responsible for expanding Impax's generic business by growing capability in the U.S. market while driving global opportunities through partnerships and actively exploring M&A opportunities. Prior to Impax, Dr. Ben-Maimon enjoyed a broad base of executive experience in the pharmaceutical industry. She was senior vice president, corporate strategy consulting to the president, chief executive officer and investors at Qualitest Pharmaceuticals, Inc. Prior to her role at Qualitest, she held executive positions with Barr Pharmaceuticals, including president and chief operating officer of Duramed Research (formerly known as Barr Research), a subsidiary of Barr Pharmaceuticals Inc. and with Teva Pharmaceuticals USA where she was senior vice president, Science and Public Policy. From 1996 to 2000, she served as senior vice president, Research and Development at Teva. She has also served as president and chief executive officer of Alita Pharmaceuticals, Inc. - a company which she founded. She served as the chairman of the board of the Generic Pharmaceutical Association from 2000 to 2003, and is also a published author of numerous scientific and clinical articles.Dr. Ben-Maimon is a graduate of Thomas Jefferson Medical College and received a bachelor of arts in biology from The University of Pennsylvania where she graduated magna cum laude. She is board certified in internal medicine, and completed clinical and research training in nephrology at Thomas Jefferson University. Read More..